TRxADE Health to acquire Superlatus, shifting to food & snack industry; new shares to be issued.

Scienture Holdings, Inc.

Superlatus shareholders receive 173,463 MEDS shares (136,436 common, 37,027 Series B preferred convertible at 100:1).
MEDS to divest its existing operating business and assets shortly after the merger closes.
Superlatus must acquire Prestige Farms and Sapientia; valuation must be at least $225M.
Combined company to create global consolidation platform for food and healthy snacks.
Merger expected to close in late Q3 or early Q4 2023; Boards unanimously approved.

item 1.01 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Scienture Holdings, Inc. entered into Agreement and Plan of Merger with Superlatus Inc. (effective 2023-06-30).

Action: entry
Agreement: merger
Counterparty: Superlatus Inc.
Effective: 2023-06-30

Exact text from the filing

On June 30, 2023, TRxADE Health, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Superlatus Inc., a Delaware corporation (“Superlatus”), and Foods Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”).

View on SEC.gov

283 material agreements filed in the last 30 days. Browse all material agreements →

Scienture Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-023016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.